| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2015
|
12.54
|
|
2
|
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
|
N Engl J Med
|
2015
|
11.98
|
|
3
|
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
|
J Clin Oncol
|
2008
|
6.64
|
|
4
|
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
|
J Clin Oncol
|
2004
|
5.06
|
|
5
|
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
|
J Clin Oncol
|
2008
|
5.04
|
|
6
|
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
|
J Clin Oncol
|
2004
|
3.67
|
|
7
|
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
|
J Clin Oncol
|
2005
|
3.28
|
|
8
|
Is patient travel distance associated with survival on phase II clinical trials in oncology?
|
J Natl Cancer Inst
|
2003
|
3.09
|
|
9
|
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
|
J Clin Oncol
|
2008
|
3.02
|
|
10
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
J Clin Oncol
|
2003
|
2.85
|
|
11
|
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
|
J Clin Oncol
|
2012
|
2.76
|
|
12
|
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
|
J Natl Cancer Inst
|
2006
|
2.61
|
|
13
|
Recommended guidelines for the treatment of cancer treatment-induced diarrhea.
|
J Clin Oncol
|
2004
|
2.51
|
|
14
|
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2005
|
2.47
|
|
15
|
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
|
Lancet Oncol
|
2009
|
2.45
|
|
16
|
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
|
J Clin Oncol
|
2008
|
2.40
|
|
17
|
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
|
J Clin Oncol
|
2009
|
2.32
|
|
18
|
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
|
J Clin Oncol
|
2005
|
2.18
|
|
19
|
Expression and mutational analysis of MET in human solid cancers.
|
Genes Chromosomes Cancer
|
2008
|
2.06
|
|
20
|
Ethnic differences and functional analysis of MET mutations in lung cancer.
|
Clin Cancer Res
|
2009
|
2.03
|
|
21
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
Cancer Res
|
2009
|
2.01
|
|
22
|
The concurrent chemoradiation paradigm--general principles.
|
Nat Clin Pract Oncol
|
2007
|
1.98
|
|
23
|
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
|
Clin Cancer Res
|
2005
|
1.97
|
|
24
|
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
|
J Clin Oncol
|
2008
|
1.91
|
|
25
|
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
|
J Clin Oncol
|
2007
|
1.91
|
|
26
|
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
|
J Clin Oncol
|
2010
|
1.90
|
|
27
|
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.
|
J Clin Oncol
|
2003
|
1.78
|
|
28
|
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
Clin Cancer Res
|
2005
|
1.75
|
|
29
|
Differences in clinical trial patient attributes and outcomes according to enrollment setting.
|
J Clin Oncol
|
2009
|
1.74
|
|
30
|
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.70
|
|
31
|
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.
|
Cancer
|
2011
|
1.70
|
|
32
|
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.
|
Clin Cancer Res
|
2008
|
1.68
|
|
33
|
The chemoradiation paradigm in head and neck cancer.
|
Nat Clin Pract Oncol
|
2007
|
1.67
|
|
34
|
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
|
Cancer Res
|
2008
|
1.60
|
|
35
|
Somatic acquisition and signaling of TGFBR1*6A in cancer.
|
JAMA
|
2005
|
1.59
|
|
36
|
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
|
J Clin Oncol
|
2005
|
1.53
|
|
37
|
The expanding role of systemic therapy in head and neck cancer.
|
J Clin Oncol
|
2004
|
1.50
|
|
38
|
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.
|
J Clin Oncol
|
2011
|
1.45
|
|
39
|
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
|
Clin Cancer Res
|
2004
|
1.44
|
|
40
|
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2006
|
1.44
|
|
41
|
New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer.
|
J Clin Oncol
|
2013
|
1.43
|
|
42
|
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
|
J Clin Oncol
|
2008
|
1.41
|
|
43
|
Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation.
|
Head Neck
|
2006
|
1.40
|
|
44
|
Aspiration in chemoradiated patients with head and neck cancer.
|
Arch Otolaryngol Head Neck Surg
|
2007
|
1.39
|
|
45
|
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.38
|
|
46
|
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
|
J Clin Oncol
|
2012
|
1.37
|
|
47
|
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
|
J Clin Oncol
|
2010
|
1.36
|
|
48
|
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
|
J Thorac Oncol
|
2010
|
1.34
|
|
49
|
Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review.
|
Int J Radiat Oncol Biol Phys
|
2003
|
1.33
|
|
50
|
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.
|
J Clin Oncol
|
2005
|
1.29
|
|
51
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
Gynecol Oncol
|
2008
|
1.29
|
|
52
|
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
|
J Biol Chem
|
2010
|
1.27
|
|
53
|
Predictors of competing mortality in advanced head and neck cancer.
|
J Clin Oncol
|
2009
|
1.27
|
|
54
|
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
|
J Clin Oncol
|
2004
|
1.26
|
|
55
|
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
|
PLoS One
|
2010
|
1.25
|
|
56
|
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
|
J Clin Oncol
|
2008
|
1.23
|
|
57
|
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.
|
Transl Res
|
2011
|
1.22
|
|
58
|
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
|
J Clin Oncol
|
2004
|
1.20
|
|
59
|
Chemoradiotherapy for locally advanced head and neck cancer.
|
J Clin Oncol
|
2007
|
1.19
|
|
60
|
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
|
Clin Cancer Res
|
2007
|
1.19
|
|
61
|
Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers.
|
Int J Oncol
|
2006
|
1.13
|
|
62
|
Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.
|
J Clin Oncol
|
2009
|
1.10
|
|
63
|
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
Invest New Drugs
|
2010
|
1.09
|
|
64
|
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
|
Int J Oncol
|
2004
|
1.09
|
|
65
|
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.
|
Mol Cancer Ther
|
2011
|
1.08
|
|
66
|
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
|
Head Neck
|
2004
|
1.08
|
|
67
|
The role of EGFR inhibition in the treatment of non-small cell lung cancer.
|
Oncologist
|
2009
|
1.07
|
|
68
|
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
|
J Thorac Oncol
|
2010
|
1.07
|
|
69
|
Locally advanced non-small cell lung cancer: the past, present, and future.
|
J Thorac Oncol
|
2008
|
1.07
|
|
70
|
Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer.
|
Head Neck
|
2007
|
1.05
|
|
71
|
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
|
Clin Cancer Res
|
2005
|
1.05
|
|
72
|
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2003
|
1.04
|
|
73
|
Chemoradiation for patients with advanced oral cavity cancer.
|
Laryngoscope
|
2010
|
1.04
|
|
74
|
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
|
J Thorac Oncol
|
2009
|
1.04
|
|
75
|
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
|
Lab Invest
|
2009
|
1.04
|
|
76
|
Personalized treatment of lung cancer.
|
Semin Oncol
|
2011
|
1.01
|
|
77
|
Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.
|
Clin Lung Cancer
|
2005
|
1.00
|
|
78
|
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
|
Clin Cancer Res
|
2003
|
1.00
|
|
79
|
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
|
J Thorac Oncol
|
2007
|
1.00
|
|
80
|
CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.
|
J Thorac Oncol
|
2012
|
1.00
|
|
81
|
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
|
Head Neck
|
2010
|
0.99
|
|
82
|
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
|
J Clin Oncol
|
2011
|
0.99
|
|
83
|
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
|
Clin Cancer Res
|
2004
|
0.99
|
|
84
|
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
|
Oral Oncol
|
2009
|
0.97
|
|
85
|
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
|
Cancer
|
2009
|
0.96
|
|
86
|
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
|
Cancer Res
|
2013
|
0.96
|
|
87
|
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
|
Cancer Invest
|
2007
|
0.96
|
|
88
|
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
|
Cancer
|
2011
|
0.95
|
|
89
|
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
|
J Thorac Oncol
|
2010
|
0.95
|
|
90
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
J Thorac Oncol
|
2008
|
0.95
|
|
91
|
Head and neck cancer in 2010: Maximizing survival and minimizing toxicity.
|
Nat Rev Clin Oncol
|
2011
|
0.94
|
|
92
|
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
Oral Oncol
|
2012
|
0.94
|
|
93
|
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
|
J Thorac Oncol
|
2014
|
0.94
|
|
94
|
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
|
J Thorac Oncol
|
2012
|
0.94
|
|
95
|
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
|
Cancer Res
|
2012
|
0.93
|
|
96
|
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
|
Med Oncol
|
2010
|
0.93
|
|
97
|
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
Invest New Drugs
|
2011
|
0.93
|
|
98
|
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
|
Am J Clin Oncol
|
2008
|
0.92
|
|
99
|
An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck.
|
Cancer
|
2002
|
0.92
|
|
100
|
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
|
Lung Cancer
|
2011
|
0.92
|
|
101
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
|
Clin Cancer Res
|
2004
|
0.92
|
|
102
|
Non-small-cell lung cancer: then and now.
|
J Clin Oncol
|
2013
|
0.92
|
|
103
|
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
|
Am J Clin Oncol
|
2011
|
0.92
|
|
104
|
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.
|
Head Neck
|
2009
|
0.92
|
|
105
|
Free-flap reconstruction in the doubly irradiated patient population.
|
Plast Reconstr Surg
|
2008
|
0.91
|
|
106
|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
|
Clin Cancer Res
|
2004
|
0.91
|
|
107
|
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
|
J Thorac Oncol
|
2012
|
0.91
|
|
108
|
Irinogenetics: what is the right star?
|
J Clin Oncol
|
2006
|
0.91
|
|
109
|
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
|
Gynecol Oncol
|
2010
|
0.91
|
|
110
|
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
|
Clin Cancer Res
|
2012
|
0.91
|
|
111
|
Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.
|
Arch Otolaryngol Head Neck Surg
|
2008
|
0.91
|
|
112
|
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
|
Cancer Chemother Pharmacol
|
2006
|
0.91
|
|
113
|
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
|
Oncologist
|
2003
|
0.90
|
|
114
|
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
|
Clin Cancer Res
|
2006
|
0.90
|
|
115
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
PLoS One
|
2013
|
0.90
|
|
116
|
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.90
|
|
117
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
Lung Cancer
|
2012
|
0.89
|
|
118
|
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.
|
Lung Cancer
|
2002
|
0.89
|
|
119
|
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.
|
Cancer Biol Ther
|
2013
|
0.89
|
|
120
|
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
|
J Thorac Oncol
|
2012
|
0.89
|
|
121
|
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.88
|
|
122
|
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
|
Cancer Biol Ther
|
2007
|
0.88
|
|
123
|
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
|
J Thorac Oncol
|
2013
|
0.87
|
|
124
|
Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer.
|
Arch Otolaryngol Head Neck Surg
|
2009
|
0.87
|
|
125
|
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.
|
Mol Cancer Ther
|
2010
|
0.87
|
|
126
|
Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer.
|
Semin Oncol
|
2008
|
0.87
|
|
127
|
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
|
J Thorac Oncol
|
2013
|
0.86
|
|
128
|
Protein kinase C beta in malignant pleural mesothelioma.
|
Anticancer Drugs
|
2008
|
0.86
|
|
129
|
MET and phosphorylated MET as potential biomarkers in lung cancer.
|
J Environ Pathol Toxicol Oncol
|
2011
|
0.86
|
|
130
|
Chemoreirradiation for recurrent salivary gland malignancies.
|
Radiother Oncol
|
2010
|
0.86
|
|
131
|
Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.
|
J Clin Bioinforma
|
2011
|
0.86
|
|
132
|
Competing roads to larynx preservation.
|
J Clin Oncol
|
2013
|
0.86
|
|
133
|
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
|
J Thorac Oncol
|
2008
|
0.85
|
|
134
|
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.
|
J Thorac Oncol
|
2010
|
0.84
|
|
135
|
Optimal therapy for unresectable stage III non-small-cell lung cancer.
|
J Clin Oncol
|
2005
|
0.84
|
|
136
|
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
|
Oncologist
|
2013
|
0.84
|
|
137
|
Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.
|
Arch Otolaryngol Head Neck Surg
|
2010
|
0.83
|
|
138
|
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
|
Head Neck Oncol
|
2011
|
0.83
|
|
139
|
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
|
J Thorac Oncol
|
2010
|
0.83
|
|
140
|
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer.
|
Radiother Oncol
|
2010
|
0.83
|
|
141
|
Chemoradiation for patients with large-volume laryngeal cancers.
|
Head Neck
|
2011
|
0.83
|
|
142
|
Differential expression of RON in small and non-small cell lung cancers.
|
Genes Chromosomes Cancer
|
2012
|
0.83
|
|
143
|
Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients.
|
Head Neck
|
2004
|
0.83
|
|
144
|
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
|
J Thorac Oncol
|
2015
|
0.83
|
|
145
|
Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma.
|
BMJ Open
|
2012
|
0.83
|
|
146
|
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
|
Clin Cancer Res
|
2003
|
0.82
|
|
147
|
Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer.
|
Oncol Rep
|
2012
|
0.82
|
|
148
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
BMC Cancer
|
2014
|
0.81
|
|
149
|
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
|
J Thorac Oncol
|
2011
|
0.81
|
|
150
|
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
|
Int J Oncol
|
2006
|
0.81
|
|
151
|
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
|
Mol Cancer Ther
|
2013
|
0.81
|
|
152
|
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.80
|
|
153
|
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.
|
Invest New Drugs
|
2005
|
0.80
|
|
154
|
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.
|
Lung Cancer
|
2003
|
0.80
|
|
155
|
Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
|
J Carcinog
|
2011
|
0.80
|
|
156
|
Key signaling pathways and targets in lung cancer therapy.
|
Clin Lung Cancer
|
2007
|
0.80
|
|
157
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
Clin Lung Cancer
|
2011
|
0.80
|
|
158
|
Cetuximab in cancers of the lung and head & neck.
|
Semin Oncol
|
2004
|
0.80
|
|
159
|
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer.
|
Am J Clin Oncol
|
2005
|
0.79
|
|
160
|
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
|
J Thorac Oncol
|
2008
|
0.79
|
|
161
|
Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement.
|
Clin Cancer Res
|
2005
|
0.79
|
|
162
|
Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
|
Invest New Drugs
|
2009
|
0.79
|
|
163
|
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
|
Cancer Chemother Pharmacol
|
2005
|
0.79
|
|
164
|
Induction chemotherapy: to use or not to use? That is the question.
|
Semin Radiat Oncol
|
2009
|
0.79
|
|
165
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
Cancer
|
2004
|
0.79
|
|
166
|
Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
|
Lung Cancer
|
2013
|
0.79
|
|
167
|
O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer.
|
J Carcinog
|
2013
|
0.79
|
|
168
|
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.
|
Oral Oncol
|
2012
|
0.79
|
|
169
|
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
|
J Thorac Oncol
|
2008
|
0.78
|
|
170
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
J Clin Oncol
|
2006
|
0.78
|
|
171
|
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
|
Cancer J
|
2005
|
0.78
|
|
172
|
Concurrent chemoradiotherapy for head and neck cancer.
|
Semin Oncol
|
2004
|
0.77
|
|
173
|
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
|
J Thorac Oncol
|
2007
|
0.77
|
|
174
|
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
|
Clin Lung Cancer
|
2009
|
0.77
|
|
175
|
Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2012
|
0.77
|
|
176
|
Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer.
|
Hematol Oncol Clin North Am
|
2004
|
0.77
|
|
177
|
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
|
Invest New Drugs
|
2004
|
0.77
|
|
178
|
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
|
J Thorac Oncol
|
2008
|
0.77
|
|
179
|
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.
|
BMC Cancer
|
2014
|
0.77
|
|
180
|
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
|
Clin Lung Cancer
|
2008
|
0.77
|
|
181
|
A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.
|
Clin Lung Cancer
|
2007
|
0.77
|
|
182
|
MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer.
|
J Carcinog
|
2009
|
0.76
|
|
183
|
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.
|
Invest New Drugs
|
2009
|
0.76
|
|
184
|
Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer.
|
Clin Lung Cancer
|
2005
|
0.76
|
|
185
|
A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.
|
J Thorac Oncol
|
2009
|
0.76
|
|
186
|
Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries.
|
Nat Rev Clin Oncol
|
2010
|
0.75
|
|
187
|
Curative treatment for advanced head and neck cancer in the community: has the time come?
|
Cancer J
|
2002
|
0.75
|
|
188
|
Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
|
Clin Lung Cancer
|
2009
|
0.75
|
|
189
|
Searching for a standard.
|
J Clin Oncol
|
2002
|
0.75
|
|
190
|
The importance of quality-of-life measurements in oncology.
|
Clin Lung Cancer
|
2002
|
0.75
|
|
191
|
Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer.
|
Lung Cancer
|
2003
|
0.75
|
|
192
|
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
|
Cancer Chemother Pharmacol
|
2002
|
0.75
|
|
193
|
Update in head and neck oncology.
|
Semin Oncol
|
2004
|
0.75
|
|
194
|
The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.75
|
|
195
|
Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck cancer.
|
Arch Otolaryngol Head Neck Surg
|
2009
|
0.75
|